Exploratory analyses suggest persistent immune remodeling after aglatimagene plus radiation in localized prostate cancer.
News|Articles|January 2, 2026
FDA updates in urology: December 2025
Author(s)Hannah Clarke
Fact checked by: Benjamin P. Saylor, Strategic Content Lead
A recap of the FDA submissions and regulatory decisions in urology from December 2025.
Advertisement
Advertisement
Welcome to Urology Times’® monthly FDA update! The year wrapped up with a flurry of regulatory approvals across prostate cancer, benign prostatic hyperplasia (BPH), and other benign conditions. Notable advances in December included clearance of the Hugo robotic system for urologic procedures as well as approvals for the ProVee and Zenflow Systems in BPH.
Related to this article
Brian Mazzarella, MD, discusses the landscape for intermediate-risk prostate cancer and early VAPOR 2 findings on water vapor ablation.
The phase 3 BiPASS trial is evaluating the use of 68Ga-PSMA-PET in combination with MRI for pre-biopsy prostate cancer detection.
In RTOG 3506, adding enzalutamide to standard ADT and salvage radiotherapy was associated with 2-year PFS benefit.
In the phase 3 PACE-A trial, SBRT and prostatectomy showed similar 8-year disease control in localized prostate cancer, with lower rates of urinary incontinence after SBRT.
Using PSMA-PET imaging and genomic testing to obtain better information earlier in the disease course changes what clinicians can do with diagnosis and treatment planning.
The registrational study is designed to evaluate the diagnostic performance of 68Ga-DOTA-RM2 vs histopathology in prostate cancer.
A limited market release of SpaceOAR Flex is expected to begin in the US later this year.
Advertisement
Advertisement